MX2023012727A - Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto. - Google Patents

Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto.

Info

Publication number
MX2023012727A
MX2023012727A MX2023012727A MX2023012727A MX2023012727A MX 2023012727 A MX2023012727 A MX 2023012727A MX 2023012727 A MX2023012727 A MX 2023012727A MX 2023012727 A MX2023012727 A MX 2023012727A MX 2023012727 A MX2023012727 A MX 2023012727A
Authority
MX
Mexico
Prior art keywords
depressive disorder
major depressive
disubstituted
postpartum depression
treating major
Prior art date
Application number
MX2023012727A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Jay Kanes
James Doherty
Handan Gunduz-Bruce
Robert Alfonso Lasser
Vijayveer Bonthapally
Ryan Arnold
Jeffrey Martin Jonas
Joi Lisa Dunbar
Bambang Senoaji Adiwijaya
Helen Anne Colquhoun
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2023012727A publication Critical patent/MX2023012727A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023012727A 2021-04-29 2022-04-29 Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto. MX2023012727A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163181743P 2021-04-29 2021-04-29
US202163197025P 2021-06-04 2021-06-04
US202163210810P 2021-06-15 2021-06-15
US202163239096P 2021-08-31 2021-08-31
US202163285812P 2021-12-03 2021-12-03
US202163289506P 2021-12-14 2021-12-14
US202163289520P 2021-12-14 2021-12-14
US202263298601P 2022-01-11 2022-01-11
PCT/US2022/026920 WO2022232504A1 (en) 2021-04-29 2022-04-29 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression

Publications (1)

Publication Number Publication Date
MX2023012727A true MX2023012727A (es) 2023-11-08

Family

ID=81748925

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012727A MX2023012727A (es) 2021-04-29 2022-04-29 Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto.

Country Status (11)

Country Link
US (1) US20240216395A1 (enExample)
EP (2) EP4768044A2 (enExample)
JP (2) JP2024515829A (enExample)
KR (1) KR20240006026A (enExample)
AU (1) AU2022266680A1 (enExample)
BR (1) BR112023022264A2 (enExample)
CA (1) CA3218072A1 (enExample)
IL (1) IL307991A (enExample)
MX (1) MX2023012727A (enExample)
TW (1) TW202308654A (enExample)
WO (1) WO2022232504A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
JP2022514510A (ja) * 2018-12-14 2022-02-14 プラクシス プレシジョン メディスンズ，インコーポレイテッド うつ病の治療方法
CA3187178A1 (en) 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof
JP2025508406A (ja) * 2022-02-16 2025-03-26 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ関連障害を処置するための神経活性ステロイド

Also Published As

Publication number Publication date
EP4329770A1 (en) 2024-03-06
CA3218072A1 (en) 2022-11-03
US20240216395A1 (en) 2024-07-04
WO2022232504A1 (en) 2022-11-03
JP2024515829A (ja) 2024-04-10
JP2025111701A (ja) 2025-07-30
TW202308654A (zh) 2023-03-01
KR20240006026A (ko) 2024-01-12
IL307991A (en) 2023-12-01
EP4768044A2 (en) 2026-07-01
AU2022266680A1 (en) 2023-11-02
BR112023022264A2 (pt) 2024-01-23

Similar Documents

Publication Publication Date Title
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
MX2022006533A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo.
MX2022010425A (es) Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
MX2023010064A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
ZA202204929B (en) Rimegepant for cgrp related disorders
BR112023022264A2 (pt) Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo
MX2020000190A (es) Métodos para tratar la insuficiencia cardíaca con activadores de sarcómero cardíaco.
WO2023004282A3 (en) Il12 receptor agonists and methods of use thereof
BR112016000804A2 (pt) Método para tratar hemorragia, choque e lesão cerebral
MX2023010728A (es) Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor.
MX2023012728A (es) Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante.
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
MY199382A (en) Methods of treating circadian rhythm sleep disorders
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
MX2024014121A (es) Metodos y composiciones para el tratamiento del exceso de glucocorticoides
ZA202212095B (en) Il4i1 inhibitors and methods of use
MX2020011817A (es) Metodos para tratar el linfoma.
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
MX2021012258A (es) Combinacion de chir99021 y acido valproico para tratar la perdida auditiva.
PH12022551493A1 (en) Synthetic triterpenoids with nitrogen-based substituents at c-17 and methods of use thereof
MX2023003583A (es) Forma cristalina del compuesto de piridinilfenilo y metodo de preparacion del mismo.
UA117243C2 (uk) Застосування ландіололу гідрохлориду у тривалому лікуванні тахіаритмії
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2022012001A (es) Tratamiento preventivo de la migra?a.